Editas Medicine (EDIT)
Develops an in vivo CRISPR candidate for lowering LDL cholesterol.
Something off on this page? Send us feedback.
Develops CRISPR-Cas9 medicines that edit genes directly inside the body, having pivoted in December 2024 from a discontinued sickle cell program to an in vivo pipeline led by an LDL-cholesterol candidate. Near-term revenue comes from licensing and collaboration payments tied to Vertex Pharmaceuticals and Bristol Myers Squibb rather than marketed products.
Grew out of CRISPR-Cas9 research at the Broad Institute, Harvard, and UC Berkeley, incorporated in 2013 as a clinical-stage biotechnology company developing genome-editing medicines.
An ex vivo cell therapy for sickle cell disease and thalassemia was discontinued in December 2024 alongside a roughly two-thirds workforce cut, resetting the business around in vivo editing delivered directly inside the body.
The lead candidate, EDIT-401, edits liver cells to lower LDL cholesterol, alongside an earlier-stage sickle cell program and a lipid-nanoparticle delivery platform aimed at additional tissues. Near-term revenue is non-dilutive, from a Vertex Pharmaceuticals license tied to the approved therapy CASGEVY and a Bristol Myers Squibb/Juno T-cell collaboration, with no marketed products yet.
Advancing the in vivo pipeline from preclinical work toward clinical trials depends on continued access to capital markets and on sustained Vertex and Bristol Myers Squibb payments.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 23, 2026 | Guggenheim | Upgrade | Rating: —Target: — | Target: $5 |
| May 5, 2026 | Chardan Capital | Reiterate | Rating: —Target: $35 | Target: $4 |
| Mar 10, 2026 | Jones Trading | Upgrade | ||
| Mar 9, 2026 | Robert W. Baird | Target | Target: $10 | Target: $6 |
| Dec 16, 2024 | JP Morgan | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $211.6M · Total debt $15.5M · Total assets $237.4M · Shareholders' equity $105.3M
- Revenue
- $11.9M
- Operating income
- −$18.6M
- Net income
- −$18.2M
No dividends on record.
| Institutions | 78.25% | 120.17M shares | |
|---|---|---|---|
| 225 holders · as of Jun 30, 2026 | |||
| Insiders | 0.37% | 564.8K shares | |
| 5 holders · as of Sep 4, 2026 | |||
| Other | 21.38% | 32.84M shares | |
| remainder | |||
153.58M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
TCG Crossover Management, LLCInstitution | 7.23% | 11.11M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.90% | 10.59M | as of Jun 30, 2026 |
Adar1 Capital Management, LLCInstitution | 5.79% | 8.89M | as of Jun 30, 2026 |
Commodore Capital LPInstitution | 5.79% | 8.89M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 5.79% | 8.89M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | Amy Parison | officer: SVP, Chief Financial Officer | −453 | $3.04 |
| Sep 3, 2026 | Linda Burkly | officer: EVP, CHIEF SCIENTIFIC OFFICER | −709 | $3.04 |
| Sep 3, 2026 | Gilmore Neil O'Neill | director, officer: CEO | −5,124 | $3.04 |
| Aug 3, 2026 | Amy Parison | officer: SVP, Chief Financial Officer | −678 | $2.58 |
| Jul 28, 2026 | Linda Burkly | officer: EVP, CHIEF SCIENTIFIC OFFICER | −4,928 | $2.67 |
- CRISPR Therapeutics
Co-owns approved CASGEVY and builds an in vivo cardiometabolic pipeline
- Intellia Therapeutics
Runs Phase 3 in vivo CRISPR liver programs nearing first FDA approval
- Beam Therapeutics
Races in vivo liver base editing and an ex vivo sickle cell cure
- Eli Lilly
Owns an acquired in vivo PCSK9 base-editing rival for LDL-C lowering
- Prime Medicine
Prime-editing biotech pivoting to Wilson's disease and AATD liver programs
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Editas Medicine | $3.07 | +5.14% | $448.1M | — | — | 9.5 | +232.3% |
| CRISPR Therapeutics | $58.31 | −1.22% | $5.69B | — | — | 425.1 | +1,041.4% |
| Intellia Therapeutics | $12.37 | −2.56% | $1.77B | — | — | 29.8 | −46.2% |
| Beam Therapeutics | $25.53 | −1.54% | $2.67B | — | — | 17.1 | −94.2% |
| Eli Lilly | $1,161.02 | −0.78% | $1.10T | 39.3 | 28.4 | 13.8 | +47.7% |
| Prime Medicine | $3.48 | −1.69% | $639.4M | — | — | 157.0 | +3.5% |
| Median | 39.3 | 28.4 | 29.8 | +3.5% |